Hansoh Pharmaceutical Co logo

3692 - Hansoh Pharmaceutical Co Share Price

HK$35 -0.5  -1.4%

Last Trade - 23/10/20

Sector
Healthcare
Size
Large Cap
Market Cap £20.43bn
Enterprise Value £18.51bn
Revenue £922.4m
Position in Universe 65th / 6000
Bullish
Bearish
Unlock 3692 Revenue
Momentum
Relative Strength (%)
1m -9.88%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 5,433 6,186 7,722 8,683 9,447 11,884 +16.9%
+8.1 +19.3 +26.6 +4.20 +26.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Hansoh Pharmaceutical Group Co Ltd revenues decreased 13% to RMB3.98B. Net income decreased 6% to RMB1.22B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Others decrease of 48% to RMB2M (income), Interest expense on lease liabilities increase from RMB40K to RMB449K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 3692
Graphical History

Revenue

3692 Revenue Unlock 3692 Revenue

Net Income

3692 Net Income Unlock 3692 Revenue

Normalised EPS

3692 Normalised EPS Unlock 3692 Revenue

PE Ratio Range

3692 PE Ratio Range Unlock 3692 Revenue

Dividend Yield Range

3692 Dividend Yield Range Unlock 3692 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
3692 EPS Forecasts Unlock 3692 Revenue
Profile Summary

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED is a China-based investment holding company principally involved in the the research and development, production and sale of pharmaceutical products. The Company’s main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company’s products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated December 2, 2015
Public Since June 14, 2019
No. of Shareholders: n/a
No. of Employees: 10,159
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng Composite LargeCap & MidCap , Hang Seng Mainland 100 ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 5,918,991,200
Free Float (0.0%)
Eligible for
ISAs
SIPPs
3692 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 3692
Upcoming Events for 3692
Frequently Asked Questions for Hansoh Pharmaceutical Co
What is the Hansoh Pharmaceutical Co share price?

As of 23/10/20, shares in Hansoh Pharmaceutical Co are trading at HK$35, giving the company a market capitalisation of £20.43bn. This share price information is delayed by 15 minutes.

How has the Hansoh Pharmaceutical Co share price performed this year?

Shares in Hansoh Pharmaceutical Co are currently trading at HK$35 and the price has moved by 43.74% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Hansoh Pharmaceutical Co price has moved by 42.79% over the past year.

What are the analyst and broker recommendations for Hansoh Pharmaceutical Co?

There are no analysts currently covering Hansoh Pharmaceutical Co.

When will Hansoh Pharmaceutical Co next release its financial results?

Hansoh Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Hansoh Pharmaceutical Co dividend yield?

Hansoh Pharmaceutical Co does not currently pay a dividend.

Does Hansoh Pharmaceutical Co pay a dividend?

Hansoh Pharmaceutical Co does not currently pay a dividend.

When does Hansoh Pharmaceutical Co next pay dividends?

Hansoh Pharmaceutical Co does not currently pay a dividend.

How do I buy Hansoh Pharmaceutical Co shares?

To buy shares in Hansoh Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Hansoh Pharmaceutical Co?

Shares in Hansoh Pharmaceutical Co are currently trading at HK$35, giving the company a market capitalisation of £20.43bn.

Where are Hansoh Pharmaceutical Co shares listed? Where are Hansoh Pharmaceutical Co shares listed?

Here are the trading details for Hansoh Pharmaceutical Co:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 3692
What kind of share is Hansoh Pharmaceutical Co?

Based on an overall assessment of its quality, value and momentum, Hansoh Pharmaceutical Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Hansoh Pharmaceutical Co share price forecast 2020?

Shares in Hansoh Pharmaceutical Co are currently priced at HK$35. At that level they are trading at 0.71% premium to the analyst consensus target price of 0.00.

Analysts covering Hansoh Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of 0.486580348 for the next financial year.

How can I tell whether the Hansoh Pharmaceutical Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hansoh Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been -4.89%. At the current price of HK$35, shares in Hansoh Pharmaceutical Co are trading at 8.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Hansoh Pharmaceutical Co PE Ratio?

The Hansoh Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 70.61. The shares are currently trading at HK$35.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Hansoh Pharmaceutical Co?

Hansoh Pharmaceutical Co's management team is headed by:

Huijuan Zhong - CHM
Aifeng Lyu - EDR
Yuan Sun - EDR
Cuifang Ma - NED
Guoqiang Lin - NID
Sheung Wai Chan - NID
Dongtao Yang - NID
Gongzheng Wu - SVP
Chunhua Zhong - SVP
Chuanhe Xu - SVP
Rudi Bao - SVP
Min Hu - VPR
Shengli Zhong - VPR
Yan Wing Li - SEC
Who are the major shareholders of Hansoh Pharmaceutical Co?

Here are the top five shareholders of Hansoh Pharmaceutical Co based on the size of their shareholding:

Zhong (Huijuan) Individual Investor
Percentage owned: 65.89% (3.90bn shares)
Cen (Junda) Individual Investor
Percentage owned: 16.05% (950.0m shares)
Boyu Capital Investment Management Limited Private Equity
Percentage owned: 3.17% (187.7m shares)
Hillhouse Capital Advisors, Ltd. Investment Advisor/Hedge Fund
Percentage owned: 2.81% (166.0m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 0.9% (53.4m shares)
Similar to 3692
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.